Mutations Conferring Drug Resistance Affect Eukaryotic Expression of HIV Type 1 Reverse Transcriptase

AIDS Research and Human Retroviruses

Volumn 20, Issue 2, 2004, Pages 191-201

  Isaguliants, Maria G ^a,b   Belikov, Sergey V ^a,c   Starodubova, Elizaveta S ^d   Gizatullin, Rinat Z ^b   Rollman, Erik ^b   Zuber, Bartek ^b   Zuber, Anne Kjerrström ^b   Andreeva, Olga I ^d   Rytting, Ann Sofie ^e   Källander, Clas F R ^e   Kochetkov, Sergey N ^d   Karpov, Vadim L ^d   Wahren, Britta ^b  

^a D I IVANOVSKY INSTITUTE OF VIROLOGY   (Russian Federation)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^e Cavidi Tech AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; RNA DIRECTED DNA POLYMERASE;

ANIMAL CELL; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; EUKARYOTE; GENE MUTATION; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOFLUORESCENCE; MONKEY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; WESTERN BLOTTING; XENOPUS LAEVIS;

ANIMALS; ANTI-HIV AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; ENZYME STABILITY; FEMALE; GENE EXPRESSION; GENES, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; OOCYTES; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; TRANSFECTION; XENOPUS LAEVIS; ZIDOVUDINE;

EID: 10744225806     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922204773004914     Document Type: Review

References (43)

1. Parniak MA and Sluis-Cremer N: Inhibitors of HIV-1 reverse transcriptase. Adv Pharmacol 2000;49:67-109.
2. Jonckeere H and de Clercq E: The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med Res Rev 2000;20:129-154.
3. Miller V and Larder BA: Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antiviral Ther 2001;6(Suppl. 3):25-44.
4. Arion D, Borkow G, Kaushik N, McCormick S, and Parniak MA: Phenotypic mechanism of HIV-1 resistance to AZT: Increased DNA polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998;37:15908-15917.
5. Mellors JW, Bazmi HZ, Scinazi RF, et al.: Novel mutations in reverse transcriptase of HIV type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob Agents Chemother 1995;39:1087-1092.
6. Young BS, Johnson M, Bahktiari D, et al: Resistance mutations in protease and reverse transcriptase genes of HIV-1 isolates from patients with combination antiretroviral therapy failure. J Infect Dis 1998;178:1497-1501.
7. Little SJ, Holte S, Routy JP, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.
8. Blower SM, Aschenbach AN, Gershengorn HB, and Kahn JO: Predicting the unpredictable: Transmission of drug-resistant HIV. Nat Med 2001;7:1016-1020.
9. Nijhuis M, Decks S, and Boucher C: Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 2001;14:23-28.
10. Pokholok DK, Gudima SO, Yesipov DS, et al.: Study on the resistance of HIV-1 to azidothymidine. I. Kinetic study of the interaction of reverse transcriptase and its mutants with substrates and azidothymidine-5′- triphosphate. Biochemistry (Moscow) 1994;57: 432-437.
11. Isaguliants MG, Pokrovskaya K, Kashuba VI et al: Eukaryotic expression of enzymatically active HIV-1 reverse transcriptase. FEBS Lett 1999;447:232-236.
12. Isaguliants MG, Gudima SO, Ivanova OV, et al.: Immunogenic properties of reverse transcriptase of HIV type 1 assessed by DNA and protein immunization of rabbits. AIDS Res Hum Retroviruses 2000;16(13):1269-1280.
13. Rytting AS, Akerblom L, Albert J, et al: Monoclonal antibodies to native HIV type 1 reverse transcriptase and their interaction with enzymes from different subtypes. AIDS Res Hum Retroviruses 2000;16:1281-1294.
14. Isaguliants MG, Petrakova NV, Zuber B, et al: DNA encoding enzymatically active HIV-1 reverse transcriptase, but not the inactive mutant, confers resistance to experimental HIV-1 challenge. Intervirology 2000;43:288-293.
15. Zuber B, Bottiger D, Benthin R, et al: An in vivo model for HIV resistance development. AIDS Res Hum Retrovirus 2001;17: 631-635.
16. Kozak M: An analysis of vertebrate mRNA sequences: Intimations of translational control. J Cell Biol 1991;115:887-903.
17. Kjerrstrom A, Hinkula J, Engstrom G, et al: Interactions of single and combined HIV-1 DNA vaccines. Virology 2001;284:46-61.
18. Lund LH, Andersson K, Zuber B, et al: Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (CEA) plasmid DNA vaccine in a murine test system. Cancer Gene Ther 2003; 10(5):365-376.
19. Robinett CC and Dunaway M: Modeling transcriptional regulation using microinjection into Xenopus oocytes. Methods: A Companion to Methods Enzymol 1999;17:151-160.
20. Nussbaum AK, Kuttler C, Hadeler KP, Rammensee HG, and Schild H: PAProC: A prediction algorithm for proteasomal cleavages available at WWW. Immunogenetics 2001;53:87-94.
21. Shirasaka T, Kavlick MF, Ueno T, Gao WY, Kojima E, Alcaide ML, Chokekijchai S, Roy BM, Arnold E, Yarchoan R, and Mitsuya H: Emergence of HIV type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995;92:2398-2402.
22. Shafer RW, Hertogs K, Zolopa AR, et al: High degree of interlaboratory reproducibility of HIV-1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol 2001;39:1522-1529.
23. Hertogs K, Bloor S, Kemp SD, et al.: Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: A survey of over 6000 samples. AIDS 2000;14:1203-1210.
24. Hertogs K, Bloor S, De Vroey V, et al: A novel HIV-1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother 2000;44:568-573.
25. Gao HQ, Boyer PL, Arnold E, Hughes SH: Effects of mutations in the polymerase domain on the polymerase, RNase H and strand transfer activities of HIV-1 reverse transcriptase. J Mol Biol 1998;277:559-572.
26. Boyer PL, Gao HQ, and Hughes SH: A mutation at position 190 of HIV-1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrob Agents Chemother 1998;42:447-452.
27. Larder BA, Purifoy DJ, Powell KL, and Darby G: Site-specific mutagenesis of AIDS virus reverse transcriptase. Nature 1987;327: 716-717.
28. Ueno T, Shirasaka T, and Mitsuya H: Enzymatic characterization of HIV-1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′-triphosphates. J Biol Chem 1995;270: 23605-23611.
29. Kaushik N, Rege N, Yadav PN, Sarafianos SG, Modak MJ, and Pandey VN: Biochemical analysis of catalytically crucial aspartate mutants of HIV-1 reverse transcriptase. Biochemistry 1996;35: 11536-11546.
30. Yu Q, Ottmann M, Pechoux C, le Grice S, and Darlix JL: Mutations in the primer grip of HIV-1 reverse transcriptase impair proviral DNA synthesis and virion maturation. J Virol 1998;72: 7676-7680.
31. Huang M, Zensen R, Cho M, and Martin MA: Construction and characterization of a temperature-sensitive HIV-1 reverse transcriptase mutant. J Virol 1998;72:2047-2054.
32. Wrobel JA, Chao SF, Conrad MJ, et al.: A genetic approach for identifying critical residues in the fingers and palm subdomains of HIV-1 reverse transcriptase. Proc Natl Acad Sci USA 1998; 95:638-645.
33. Weiss KK, Isaacs SJ, Tran NH, Adman ET, and Kim B: Molecular architecture of the mutagenic active site of HIV type 1 reverse transcriptase: Roles of the beta 8-alpha E loop in fidelity, processivity, and substrate interactions. Biochemistry 2000;39:10684-10694.
34. Larder BA, Kemp SD, and Purifoy DJM: Infectious potential of HIV-1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc Natl Acad Sci USA 1989;86:4803-4807.
35. Goudsmit J, De Ronde A, Ho DD, and Perelson AS: HIV fitness in vivo: Calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J Virol 1996;70: 5662-5664.
36. Harrigan PR, Bloor S, and Larder BA: Relative replicative fitness of zidovudine-resistant HIV-1 isolates in vitro. J Virol 1998; 72:3773-3778.
37. Imamichi T, Berg SC, Imamichi H, et al: Relative replication fitness of a high-level 3′-azido-3′-deoxythymidine-resistant variant of HIV-1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr → Gly) at codon 69. J Virol 2000; 74:10958-10964.
38. Archer RH, Dykes C, Gerondelis P, et al: Mutants of HIV-1 transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J Virol 2000;74: 8390-8401.
39. Yahi N, Tamalet C, Tourres C, et al: Mutation patterns of the reverse transcriptase and protease genes of HIV-1-infected patients undergoing combination therapy: Survey of 787 sequences. J Clin Microbiol 1999;37:4099-4106.
40. Eshleman SH, Mracna M, Guay LA, et al.: Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15:1951-1957.
41. Back NK, Nijhuis M, Keulen W, et al: Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996;15: 4040-4049.
42. Layne SP, Merges MJ, Dembo M, et al: Factors underlying spontaneous activation and susceptibility to neutralization of human immunodeficiency virus. J Virol 1992;189:695-714.
43. Brenner BG, Routy JP, Petrella M, et al: Persistence and fitness of multidrug-resistant HIV-1 acquired in primary infection. J Virol 2002;76:1753-1761.